442-N RNA primed SMAR-TTMcells against multiple driver mutations, all HLA’s, designed for first line therapy
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
DOI:
10.1136/jitc-2023-sitc2023.0442-n
Publication Date:
2023-10-31T15:07:34Z
AUTHORS (7)
ABSTRACT
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....